328 results on '"L. Pour"'
Search Results
2. B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
- Author
-
P. Musto, M.C. Minnema, W.W.H. Roeloffzen, A. Capra, B. van der Holt, A. Juul Vangsted, A. Broyl, F. Schjesvold, T. Lund, T. Silkjaer, R. Benjamin, M. Grasso, K. Lung Wu, J. Caers, M. Cavo, R. Hájek, B. Bruno, A. Gadisseur, G. Pietrantuono, M. Offidani, L. Pour, P. Sonneveld, M. Boccadoro, and N. van de Donk
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
3. P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
- Author
-
M. Vlachová, M. Štork, S. Ševčíková, T. Jelínek, J. Minařík, J. Radocha, P. Krhovská, L. Pospíšilová, I. Špička, J. Straub, P. Pavlíček, A. Jungová, V. Sandecká, V. Maisnar, R. Hájek, and L. Pour
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
4. PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
- Author
-
M. Vlachová, J. Gregorová, S. Adamová, L. Pečinka, L. Moráň, V. Porokh, M. Štork, L. Pour, J. Havel, P. Vaňhara, and S. Ševčíková
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
5. EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001
- Author
-
X. Leleu, M. Beksac, T. Chou, M.A. Dimopoulos, S. Yoon, H.M. Prince, A. Chari, A. Oriol, D.S.D. Siegel, M. Khurana, M. Qi, M. Obreja, L. Pour, and T. Shelekhova
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2020
- Full Text
- View/download PDF
6. Investigation into the Role of Information and Communication Technology at University's Education
- Author
-
L. Pour Mohammad Baqer and E. Pour Mohammad Baqer
- Subjects
information and communication technology ,education ,learning ,university ,Special aspects of education ,LC8-6691 - Abstract
It is certain that the present world, in fact the world of information technology and the world of hasty history, is different because of changes. Education systems in society and university are not detached from other sociable and national organizations and from extensive international changes in global village, since education society is the center of changes and alternations both in historical experience and special condition at present century. Education systems will be changed in the future because there is transformation in social organization of human being but the most important issue is that those kinds of strategies should be used in which education systems at universities are not imitation but recreate themselves in sync with human's development. This paper investigates information and communication technology and its application at university education in different courses of teaching, learning, educational help devices, imaginary libraries and distance education. Then there are different propositions about improving education at universities.
- Published
- 2008
- Full Text
- View/download PDF
7. P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
- Author
-
M Mateos, M Szarejko, J Bila, F Schjesvold, I Spicka, V Maisnar, A Jurczyszyn, Z Grudeva-Popova, R Hajek, G Usenko, M Thuresson, S Norin, S Jarefors, P Richardson, and L Pour
- Subjects
Hematology - Published
- 2023
8. Retroperitoneal fibrosis - diagnosis and treatment
- Author
-
Z, Adam, A, Čermák, Z, Adamová, Z, Řehák, R, Koukalová, and L, Pour
- Subjects
Humans ,Retroperitoneal Fibrosis ,Glucocorticoids ,Immunosuppressive Agents - Abstract
Idiopathic retroperitoneal fibrosis (IRF) is a rare condition characterized by the development of a peri-aortic and peri-iliac tissue showing chronic inflammatory infiltrates and pronounced fibrosis. Ureteral entrapment with consequent obstructive uropathy is one of the most common complications which can lead to acute renal failure and, in the long term, to varying degrees of chronic kidney disease. Common symptoms at onset include lower back, abdominal or flank pain. Pain is frequently referred to the hip, to the groin and to the lateral regions of the leg, often with nocturnal exacerbations and not responding to position changes. The disease is commonly associated with signs of systemic inflammatory response (malaise, fever, and anorexia and weight loss). Glucocorticoids are considered the cornerstone of the therapy. The use of other immunosuppressive agents, including cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil and biological agents such as rituximab, tocilizumab and infliximab have been reported as a valuable option mostly in case reports, cases series and small studies. These agents allowed to reduce cumulative dose of glucocorticoids and their adverse effects. Combined therapy is preferable for all patients who suffer from significant glucocorticoid- related toxicity or in cases where glucocorticoids alone are insufficient to treat the condition.
- Published
- 2022
9. Léčba Castlemanovy choroby siltuximabem - popis případu a přehled literatury.
- Author
-
Z., Adam, D., Zeman, A., Chodacki, L., Pour, T., Horváth, P., Benda, Z., Adamová, M., Krejčí, M., Tomíška, I., Boichuk, and Z., Král
- Published
- 2023
- Full Text
- View/download PDF
10. Přínos empatie lékaře pro jeho pacienty a výsledky začlenění rozvíjení schopnosti empatie do kurikul lékařských fakult .
- Author
-
Z., Adam, J., Klimeš, Z., Boleloucký, L., Pour, Z., Adamová, M., Tomíška, and H., Marečková
- Published
- 2022
- Full Text
- View/download PDF
11. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
- Author
-
Ashraf Badros, Nizar J. Bahlis, Roman Hájek, Larry D. Anderson, Vadim A Doronin, Meletios A. Dimopoulos, Jacqueline Jeha, Halyna Pylypenko, Jatin P. Shah, Reuben Benjamin, Sebastian Grosicki, Maria Gavriatopoulou, Dinesh Kumar Sinha, Xavier Leleu, Thierry Facon, Tuphan Kanti Dolai, Michele Cavo, Don A. Stevens, Moshe Yair Levy, Iryna Kriachok, Sundar Jagannath, L. Pour, Paul G. Richardson, Holger W. Auner, Maria V. Mateos, Sharon Shacham, Sosana Delimpasi, Hang Quach, Yi Chai, Mamta Garg, Michael Kauffman, Ivan Spicka, Maryana Simonova, Philippe Moreau, Christopher P. Venner, Ganna Usenko, Melina Arazy, Karyopharm, Mateos M.V., Gavriatopoulou M., Facon T., Auner H.W., Leleu X., Hajek R., Dimopoulos M.A., Delimpasi S., Simonova M., Spicka I., Pour L., Kriachok I., Pylypenko H., Doronin V., Usenko G., Benjamin R., Dolai T.K., Sinha D.K., Venner C.P., Garg M., Stevens D.A., Quach H., Jagannath S., Moreau P., Levy M., Badros A.Z., Anderson L.D., Bahlis N.J., Cavo M., Chai Y., Jeha J., Arazy M., Shah J., Shacham S., Kauffman M.G., Richardson P.G., and Grosicki S.
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,SINE compound ,Selinexor ,Dexamethasone ,Bortezomib ,03 medical and health sciences ,0302 clinical medicine ,Multiple myeloma ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Hydrazine ,Humans ,Diseases of the blood and blood-forming organs ,1112 Oncology and Carcinogenesis ,Adverse effect ,Molecular Biology ,Letter to the Editor ,1102 Cardiorespiratory Medicine and Haematology ,RC254-282 ,Lenalidomide ,Antineoplastic Combined Chemotherapy Protocol ,Science & Technology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Exportin-1 ,Hematology ,Triazoles ,medicine.disease ,Regimen ,030104 developmental biology ,Prior Therapy ,Hydrazines ,030220 oncology & carcinogenesis ,Proteasome inhibitor ,Female ,RC633-647.5 ,business ,Life Sciences & Biomedicine ,medicine.drug ,Human - Abstract
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase 3 BOSTON study, once weekly selinexor, once weekly bortezomib, and 40 mg dexamethasone (XVd) demonstrated a significantly longer median progression-free survival (PFS), higher response rates, deeper responses, a trend to improved survival, and reduced incidence and severity of bortezomib-induced peripheral neuropathy when compared with standard twice weekly bortezomib and 80 mg dexamethasone (Vd). The pre-specified analyses described here evaluated the influence of the number of prior lines of therapy, prior treatment with lenalidomide, prior proteasome inhibitor (PI) therapy, prior immunomodulatory drug therapy, and prior autologous stem cell transplant (ASCT) on the efficacy and safety of XVd compared with Vd. In this 1:1 randomized study, enrolled patients were assigned to receive once weekly oral selinexor (100 mg) with once weekly subcutaneous bortezomib (1.3 mg/m2) and 40 mg per week dexamethasone (XVd) versus standard twice weekly bortezomib and 80 mg per week dexamethasone (Vd). XVd significantly improved PFS, overall response rate, time-to-next-treatment, and showed reduced all grade and grade ≥ 2 peripheral neuropathy compared with Vd regardless of prior treatments, but the benefits of XVd over Vd were more pronounced in patients treated earlier in their disease course who had either received only one prior therapy, had never been treated with a PI, or had prior ASCT. Treatment with XVd improved outcomes as compared to Vd regardless of prior therapies as well as manageable and generally reversible adverse events. XVd was associated with clinical benefit and reduced peripheral neuropathy compared to standard Vd in previously treated MM. These results suggest that the once weekly XVd regimen may be optimally administered to patients earlier in their course of disease, as their first bortezomib-containing regimen, and in those relapsing after ASCT.Trial registration: ClinicalTrials.gov (NCT03110562). Registered 12 April 2017. https://clinicaltrials.gov/ct2/show/NCT03110562.
- Published
- 2021
12. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone
- Author
-
Michele Cavo, Sundar Jagannath, Reuben Benjamin, Ganna Usenko, Sebastian Grosicki, Maryana Simonova, Xavier Leleu, Larry D. Anderson, Moshe Yair Levy, Hang Quach, Sosana Delimpasi, Ivan Spicka, Mamta Garg, Thomas Illmer, L. Pour, Paul G. Richardson, Nizar J. Bahlis, Hailin Yu, Jatin P. Shah, Shijie Tang, Christopher P. Venner, Hoyee Leong, Meletios A. Dimopoulos, Larysa Sanchez, Jennifer L. Beaumont, Don A. Stevens, Sharon Shacham, Iryna Kriachok, Thierry Facon, Yi Chai, Michael Kauffman, Holger W. Auner, Roman Hájek, Dinesh Kumar Sinha, Xiwen Ma, Stacie Hudgens, Sanchez L., Leleu X., Beaumont J.L., Yu H., Hudgens S., Simonova M., Auner H.W., Quach H., Delimpasi S., Spicka I., Pour L., Kriachok I., Dimopoulos M.A., Usenko G., Hajek R., Benjamin R., Sinha D.K., Venner C., Illmer T., Garg M.K., Stevens D.A., Jagannath S., Levy M., Anderson L.D., Bahlis N.J., Facon T., Cavo M., Chai Y., Ma X., Tang S., Leong H., Shah J., Shacham S., Kauffman M., Richardson P., Grosicki S., and Karyopharm
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Immunology ,Pain ,Dexamethasone ,Bortezomib ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Hydrazine ,Humans ,1102 Cardiorespiratory Medicine and Haematology ,Multiple myeloma ,Aged ,Science & Technology ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Peripheral Nervous System Diseases ,Hematology ,Triazoles ,medicine.disease ,Hydrazines ,Peripheral neuropathy ,Female ,Peripheral Nervous System Disease ,business ,Previously treated ,Multiple Myeloma ,Life Sciences & Biomedicine ,medicine.drug ,Human - Abstract
NA
- Published
- 2021
13. Plasma Cell Leukemia – the Forgotten Disease
- Author
-
Sabina Ševčíková, L Pour, D Vrábel, Marta Krejčí, M Žárska, M Jarošová, Martin Stork, Z Adam, and Renata Bezdekova
- Subjects
Plasma cell leukemia ,Oncology ,medicine.medical_specialty ,business.industry ,Clinical course ,Retrospective cohort study ,medicine.disease ,Leukemia, Plasma Cell ,Monoclonal gammopathy ,Rare Diseases ,Autologous stem-cell transplantation ,Internal medicine ,medicine ,Humans ,In patient ,medicine.symptom ,Stage (cooking) ,business ,Multiple myeloma - Abstract
Background Plasma cell leukemia (PCL) is a rare dis-ease and possibly the most aggressive form of monoclonal gammopathy. It is classified into two forms - primary PCL that occurs without a previously identifiable multiple myeloma stage, and secondary PCL that develops from previously dia-gnosed multiple myeloma. These two forms have different cytogenetic and molecular profiles, but both forms have an aggressive clinical course. Combinations of different therapeutic approaches includ-ing autologous stem cell transplantation and currently proteasome inhibitors and immunomodulatory drugs are used to treat PCL. Current dia-gnostic criteria, developed in the 1970s, may underestimate PCL prevalence; thus, prospective re-evaluation is be-ing considered. Purpose The aim of this study is to review all available information about PCL with an emphasis on dia-gnostics, treatment, and circulat-ing plasma cells features. Conclusion Although PCL is rare, it is quite a severe dis-ease. Current treatments us-ing the latest therapeutics have prolonged patient survival. However, due to the low incidence of PCL, information about the dis-ease is very limited and comes mostly from small retrospective studies. Further studies of PCL are needed, because new information could increase in patient survival and our understand-ing of its pathogenesis. Key words plasma cell leukemia - multiple myeloma - plasma cells - cytogenetics - treatment This work was supported by grant NV18-03-00203. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submited: 2. 11. 2018 Accepted: 18. 11. 2018.
- Published
- 2019
14. [MicroRNA Analysis for Extramedullary Multiple Myeloma Relapse]
- Author
-
J, Gregorová, D, Vrábel, L, Radová, N A, Gablo, M, Almaši, M, Štork, O, Slabý, L, Pour, J, Minařík, and S, Ševčíková
- Subjects
MicroRNAs ,Recurrence ,High-Throughput Nucleotide Sequencing ,Humans ,Bayes Theorem ,Bone Marrow Cells ,Pilot Projects ,Neoplasm Recurrence, Local ,Multiple Myeloma - Abstract
Multiple myeloma (MM) is the second most common hematooncological disease. Patient survival has been greatly improved by the introduction of new drugs into clinical practice, but survival is negatively affected by the so-called extramedullary relapse (EM), caused by the loss of plasma cell dependence on the bone marrow microenvironment and their migration out of the bone marrow. The nature and causes of this process are currently unclear. MicroRNAs (miRNAs) are short, non-coding RNA molecules involved in many physiological and pathological processes. Their significance in the pathogenesis of MM has been demonstrated by several studies. We assume that they are also involved in the development of the EM. The aim of this study was to analyze different miRNA expression between MM and EM patients.Using next generation sequencing, we analyzed 39 samples of bone marrow cells from MM patients at diagnosis and 9 bone marrow plasma samples of EM patients.In total, 2,278 miRNA were sequenced, but only 658 miRNAs were analyzed as they were expressed in all samples and had at least 20 reads. Expression data were generated using the Chimira tool from fastq data. All sequences were mapped using miRBase v20. Further analyses were performed using the R/Bioconductor package. The Bayesian procedure was used for normalization of expression. P values were adjusted using the Benjamini-Hochberg method. Analysis found 10 miRNA (p0.0005) that are statistically significantly expressed in EM vs. MM patients - these are miR-26a-5p, miR-26b-5p, miR-30e-5p, miR-424-3p, miR-503-5p, miR-767-5p, miR-105-5p, miR-5695-5p, miR-450b-5p and miR-92b-3p. These miRNAs will be further verified by qPCR method on a larger set of MM and EM patients.Our pilot study has shown that there are differentially expressed miRNAs between MM and EM patients.Key words: multiple myeloma - microRNA - carcinogenesis - next generation sequencing The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papersThis work was supported by grant MZ ČR AZV 17- 29343A. Submitted: 17. 3. 2018Accepted: 20. 3. 2018.
- Published
- 2018
15. PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION
- Author
-
L. Pour, A. Meckl, H. Einsele, S. Knop, D. Lechner, A. Egle, Katja Weisel, H. Ludwig, Holger Rumpold, T. Melchardt, E. Gunsilius, W. Willenbacher, N. Zojer, D. Niederwieser, R. Greil, T. Jelinek, W. Pönisch, K.J. Krenosz, Axel Hinke, M. Schreder, R. Hajek, S. Nolte, and A. Petzer
- Subjects
Oncology ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Hematology ,Ixazomib ,chemistry.chemical_compound ,chemistry ,Maintenance therapy ,Quality of life ,Internal medicine ,medicine ,In patient ,business ,education - Published
- 2019
16. PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR
- Author
-
L. Pour, Enrique M. Ocio, M. Granell, J. Martinez-Lopez, M. Sydvander, M.V. Mateos, A. Oriol, R. Hajek, Christian Jacques, Jan Straub, P.G. Richardson, M. Norkin, Y.A. Efebera, V. Maisnar, C. Byrne, L. Karlin, K. Le Du, J.-R. Eveillard, J. Delaunay, and V. Ribrag
- Subjects
Bortezomib ,business.industry ,Daratumumab ,Hematology ,medicine.disease ,Refractory ,Relapsed refractory ,Cancer research ,medicine ,Proteasome inhibitor ,business ,Multiple myeloma ,Dexamethasone ,medicine.drug - Published
- 2019
17. Total phenolics, flavonoids content and antioxidant capacities of grape pomace fermented by Aspergillusoryzae
- Author
-
R Ashrafi Yorghanloo, M Alizadeh Khaledabad, M Rezazad Bari, and L Pour Akbar
- Subjects
Flavonoids ,lcsh:Food processing and manufacture ,lcsh:TP368-456 ,fungi ,grape pomace ,food and beverages ,Aspergillusoryzae ,Phenolic compounds - Abstract
Antioxidants due to the extensive biological properties and their role in preventing of various diseases, are considered as components of health. Grape pomacevitisviniferacv.rish baba contains high amounts of antioxidant compounds. Fermentation of grape pomace by Aspergillusoryzae increases the extraction of these compounds. Ultrasound – assisted extraction is the most important methods for the extraction of valuable compounds from plant sources and accelerates the rate of extraction. The aim of this study was to evaluate of various factors effect on the extraction of phenolic compounds, flavonoids and antioxidant properties of grape pomace fermented by Aspergillusoryzae and using response surface methodology. The variables were temperature (55-67°c), time (24-32 min), solvent concentration (37-49%) and whey powder content (10-50gr). The highest rate of phenolic compounds and flavonoids were obtained at 64°c for 30 min and the solvent concentration of 46%. The highest level of DPPH and FRAP were obtained at 58°c for 30 min and the solvent concentration of 46%. With increasing extraction time phenolic compounds, flavonoids, DPPH and FRAP were ascending. Obtained results proved that fermentation by Aspergillusoryzae and using ultrasound – assisted extraction was a suitable method for the extraction of biological material from grape pomace with benefites such as high extraction rate, reducing the amount of solvent, temperature and time required.
- Published
- 2015
18. Stillova nemoc - vzácné autoinflamatorní onemocnění dospělých: popis případu a přehled léčebných možností.
- Author
-
Z., Král, M., Krejčí, Z., Řehák, R., Koukalová, L., Pour, M., Krtička, and Z., Adam
- Abstract
Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
19. Nekrobiotický xantogranulom asociovaný s monoklonální gamapatií: popis případu a přehled léčebných možností.
- Author
-
Z., Král, M., Krejčí, J., Kynclová, Z., Řehák, R., Koukalová, Š., Skorkovská, L., Pour, and Z., Adam
- Abstract
Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
20. Léčba Erdheimovy-Chesterovy choroby.
- Author
-
Z., Král, M., Krejčí, M., Ježová, S., Ševčíková, Z., Řehák, R., Koukalová, L., Pour, and Z., Adam
- Abstract
Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
21. PHENOTYPIC AND MOLECULAR DIFFERENTIATION OF PECTOBACTERIUM AND DICKEYA SPP. CAUSING POTATO TUBER AND STEM ROT IN NORTH-WESTERN PROVINCES OF IRAN
- Author
-
L, Pour, M, Mohammadi, G, Khodakaramian, and B Soheili, Moghadam
- Subjects
Plant Tubers ,Phenotype ,Enterobacteriaceae ,Pectobacterium ,Iran ,Plant Diseases ,Solanum tuberosum - Abstract
Iran is one of the most important potato-producing countries in Asia and Oceania. Approximately 20 percent of potato cultivation in Iran occurs in the North-western provinces. Pectobacterium and Dickeya species cause important diseases in potato crop. They may incite blackleg and are responsible for tuber soft rot in storage, thereby reducing yield and quality. In order to identify and differentiate the species of soft rot bacteria, potato stems and tubers showing soft rot symptoms were collected from potato fields in North-western Iran. A total of fifty strains belonging to Pectobacterium and Dickeya species were isolated and identified from the infected tissues. Phenotypic characterization revealed a considerable variation among strains thus dividing them into five separate groups. Group 1 strains belonged to Dickeya chrysanthemi that were different from the type strain in malonate utilization. Group 2 strains were similar to Pectobacterium betavascularum but were different from the type strain in utilization of raffinose, citrate and D-sorbitol. Group 3 strains showed more resemblance to P. wasabiae but were different from the type strain with respect to acetoin production. Group 4 strains belonged to P. carotovorum subsp. carotovorum (Pcc) and group 5 strains were identified as intersubspecific of Pcc and P. carotovorum subsp. odoriferum. Polymerase chain reaction using pelY primers identified strains belonging to Pectobacterium species but not P. betavascularum.
- Published
- 2016
22. Epidemiology of Plasma Cell Leukemia in the Czech Republic.
- Author
-
Zapletalova, M., Krejci, D., Jarkovský, J., Muzik, J., and Dusek, L. L. Pour
- Published
- 2019
- Full Text
- View/download PDF
23. S imunoglobulinem IgG4 asociované onemocnění.
- Author
-
Z., Adam, M., Krejčí, Z., Chovancová, Z., Řehák, R., Koukalová, M., Štork, A., Čermák, L., Říhová, and L., Pour
- Abstract
Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
24. Chronická recidivující kopřivka, bolesti kostí i kloubů, horečka nejasného původu a monoklonální imunoglobulin typu IgM = syndrom Schnitzlerové.
- Author
-
Z., Adam, R., Koukalová, M., Krejčí, Z., Čermáková, E., Vetešníková, L., Pour, V., Sandecká, M., Štork, Z., Řehák, E., Pourová, A., Čermák, Z., Král, and J., Mayer
- Abstract
Copyright of Transfusiology & Haematology Today / Transfuze a Hematologie Dnes is the property of Czech Medical Association of JE Purkyne and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
25. [Six-year follow-up of a patient with multiple angiomatosis involving skeleton, thoracic and abdominal cavities and the gut wall]
- Author
-
Z, Adam, M, Matýšková, M, Tomíška, Z, Rehák, R, Koukalová, L, Křikavová, L, Pour, M, Krejčí, P, Szturz, L, Zahradová, M, Mechl, M, Moulis, J, Vaníček, C, Neuman, M, Navrátil, K, Veselý, R, Hájek, and J, Mayer
- Subjects
Adult ,Male ,Angiomatosis ,Abdominal Neoplasms ,Humans ,Bone Neoplasms ,Thoracic Neoplasms - Abstract
Multiple angiomatosis is a rare disease causing angiomatous lesions in multiple organs and tissues with a risk of life-threatening haemorrhage.A young man was diagnosed with multiple angiomatosis at the age of 28 after two years of back and abdominal pain. Laparotomy revealed multiple spongy lesions mostly within the retroperitoneal space. Also, an involvement of the gut wall, bones and mediastinum was evident. After 6 years of treatment, the disease has been stabilized. Bone pain ceased with a significant contribution of zoledronate. Using CT and MR imaging, the effectiveness of antiangiogenic drugs was evaluated. Furthermore, treatment response was evaluated using laboratory values for coagulation and blood count, as angiomatous proliferation is known to be associated with disseminated intravascular coagulation and anaemia.Baseline laboratory examination revealed elevated D-dimer (more than 20 µg/mL), low fibrinogen (1.4 g/L), and the presence of fibrin monomers. After treatment with 6 mil. IU of interferon-alpha thrice weekly, there was only partial improvement in D-dimer (17.2 µg/mL) and fibrinogen (1.5 g/L) concentrations but fibrin monomers remained positive. After thalidomide (100 mg daily), D-dimer decreased to 6.1 µg/mL and fibrinogen levels increased to 1.9 g/L with the disappearance of fibrin monomers. CT scanning showed significant regression of angiomatous lesions. Progressive neuropathy was the reason to lower the dose of thalidomide by half and this caused D-dimer to rise again. Switching to lenalidomide 10 mg daily led to an increase in D-dimer to 10.8 µg/mL and decrease in haemoglobin concentration to 124 g/L. Fibrin monomers became positive again. Combined therapy with thalidomide (50 mg/day) and lenalidomide (10 mg days 1-21 in 28-day cycles) has led to stabilisation of the disease. Median concentration of haemoglobin increased to 131 (84-141) g/l. The median of D-dimer decreased to 9.3 (8.0-17) µg/mL.Thalidomide in the dose of 100 mg daily led to better stabilisation of the disease than interferon-alpha. However, lowering the dose because of adverse effects failed to be effective sufficiently. Lenalidomide 10 mg daily was well-tolerated but insufficient to improve D-dimer and haemoglobin concentrations. Therefore, for further treatment we have decided to use the combination of lenalidomide and thalidomide in doses of 10 mg and 50 mg, respectively because both drugs have desirable antiangiogenic activities with different adverse effect profiles. On this therapy, the patients disease has been stable for 9 months.
- Published
- 2012
26. [Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide]
- Author
-
Z, Adam, A, Sprláková, Z, Rehák, R, Koukalová, P, Szturz, M, Krejcí, L, Pour, L, Zahradová, L, Cervinek, L, Kren, M, Moulis, M, Hermanová, M, Mechl, J, Prásek, R, Hájek, Z, Král, and J, Mayer
- Subjects
Adult ,Male ,Radiography, Abdominal ,Erdheim-Chester Disease ,Bone Marrow ,Remission Induction ,Brain ,Cladribine ,Humans ,Tomography, X-Ray Computed ,Lenalidomide ,Magnetic Resonance Imaging ,Thalidomide - Abstract
Erdheim-Chester disease is a very rare syndrome affecting adult population. It typically causes hyperostosis of long bones, retroperitoneal fibrosis and widening of the aortic wall. Patients frequently suffer from disease-associated fevers and pain in the lower limbs. No guidelines are available for the treatment of this rare ailment. Therefore, we describe our experience with lenalidomide in a patient with poor treatment response to 2-chlorodeoxyadenosine.Diabetes insipidus and neurological problems developing over 4 years were the first signs of the disease. The disease was diagnosed from histology of the bone marrow extracted from the ilium. At diagnosis, the patient had multiple infiltrates in the brain, widened wall of the thoracic and abdominal aorta, fibrotic changes to retroperitoneum and typical hyperostosis of the long bones of lower limbs with high accumulation of technetium pyrophosphate as well as fluorodeoxyglucose. First line treatment involved 2-chlorodeoxyadenosine 5 mg/m2 s.c. for 5 consecutive days every 28 days. There was no clear treatment response identifiable on the MR scan of the brain following the third cycle and thus 4th-6th cycle consisted of 2-chlorodexyadenosine 5 mg/m2 + cyclophosphamide 150 mg/m2 + dexamethasone 24 mg day 1-5 every 28 days. After the 6th cycle, MR showed partial regression of the brain lesions. PET-CT showed an increased accumulation of fluorodeoxyglucose in bone lesions. Second line treatment involved lenalidomide 25 mg/day days 1-21 every 28 days. Lenalidomide tolerance was excellent; the number of neutrophils and thrombocytes was within the physiological range throughout the treatment period. Follow-up MR showed complete remission of the brain lesions, while follow-up PET-CT showed further increase in fluorodeoxyglucose accumulation in the bones of lower limbs.Treatment with 2-chlorodeoxyadenosine-based regimen provided partial remission of Erdheim-Chester disease lesions in the brain, while treatment with lenalidomide resulted in complete remission of these lesions. Fluorodeoxyglucose continues to accumulate in the long bones of lower limbs. We are unable to elucidate the reasons for complete remission of the disease in the brain as per the MR and its progression in the long bones according to PET-CT. Further testing of lenalidomide in the treatment of this disease is required to support further use of this perspective treatment option.
- Published
- 2011
27. Impact of nestin analysis in multiple myeloma
- Author
-
H, Sváchová, L, Kovárová, J, Stossová, A, Potácová, L, Pour, and R, Hájek
- Subjects
Nestin ,Intermediate Filament Proteins ,Biomarkers, Tumor ,Humans ,Nerve Tissue Proteins ,Multiple Myeloma - Abstract
Nestin, a marker of multipotent precursor cells, is an important dynamic structure; its polymerization/depolymerization influences intracellular signaling and participates in key cell processes such as proliferation, migration and cell survival. It is presumed that nestin plays a central role in carcinogenesis. It is suggested that nestin might be a suitable diagnostic and prognostic indicator of malignancy and a potential marker of cancer stem cells. Unexpectedly, nestin has been identified in mature CD138+CD38+ plasma cells (PC) of multiple myeloma patients (MM). Expression of nestin, a marker of stem/progenitor cells, in malignant PC, that are considered to be terminally differentiated, indicates that nestin might play a unique role in pathology of MM.
- Published
- 2011
28. Multiple myeloma
- Author
-
R, Hájek, M, Krejcí, L, Pour, and Z, Adam
- Subjects
Humans ,Multiple Myeloma ,Prognosis - Abstract
This manuscript is an introduction to the topic of multiple myeloma. Definition, incidence, etiology, pathogenesis and principles of diagnostics and treatment of multiple myeloma are described briefly in this work It corresponds with Guidelines for diagnostics and treatment of the myeloma section of the Czech Hematological Society and the Czech Myeloma Group.
- Published
- 2011
29. [Successful treatment of angiomatosis with thalidomide and interferon alpha. A description of five cases and overview of treatment of angiomatosis and proliferating hemangiomas]
- Author
-
Z, Adam, L, Pour, M, Krejcí, E, Pourová, O, Synek, L, Zahradová, M, Navrátil, M, Mechl, T, Nebeský, J, Neubauer, J, Feit, J, Vokurková, Z, Král, O, Bednarík, P, Slampa, H, Dolezalová, R, Hájek, and J, Mayer
- Subjects
Adult ,Male ,Angiomatosis ,Humans ,Interferon-alpha ,Angiogenesis Inhibitors ,Female ,Middle Aged ,Hemangioma ,Aged ,Thalidomide - Abstract
Our paper describes 5 patients with a vascular malformation - angiomatosis. In the first patient, a young man, angiomatosis affected the stomach, intestine, the area of mesenterium and retroperitoneum as well as mediastinum. Angiomatous mass had invaded pelvic bones and vertebrae. Treatment was initiated with interferon alpha in a maximum tolerated dose of 3 million units 3 times a week. Because of low efficacy of interferon alpha, thalidomide was added at a dose of 100 mg per day. Bone pain disappeared following a few applications of zoledronate administered in regular monthly intervals. After 3 years of concomitant administration of interferon alpha and thalidomide, we changed the regimen due to adverse effects and are administering thalidomide and interferon alternatively in 4-monthly intervals. Treatment has resulted in 50% reduction, according to imaging, of angiomatous mass, reduced intensity of disseminated intravascular coagulation and disappearance of clinical signs. The second was a case of multiple angiomatosis affecting the intestine only (multiple intestinal angiodysplasias) where we used thalidomide monotherapy. This treatment reduced blood losses and haemoglobin concentrations rose to normal levels. This male patient had consumed 120 transfusion units per year before the initiation of thalidomide. The third case was a slowly progressing vascular malformation of the face. This vascular malformation troubled its sufferer by spontaneous shortening that could not be resolved surgically because of its fragility. Two years of combined treatment with interferon a 6 million unites 3 times a week and thalidomide 100 mg daily led to a reduction and flattening of the malformation, paling of its colour and ceasing of spontaneous bleeding. This development enabled minor surgery--partial excision of this large vascular malformation. Histology examination confirmed that there was no evidence of new capillary formation. Histological examination thus confirmed efficacy of the treatment. The fourth case involved a patient with large vascular malformations affecting supraclavicular region of the neck and nape in whom radiotherapy was applied (54 Gy) leading to a reduction of the malformation mass by a at least 50%. The fifth is a case of an extensive periorbital lymphangioma that diminished following treatment with interferon alpha. These cases illustrate the benefits of combined treatment including thalidomide and interferon alpha in patients with multiple angiomatosis or large proliferating hemangioma (vascular malformation). If combined treatment with thalidomide and interferon a is not possible, it is beneficial to use thalidomide monotherapy. Radiotherapy is another alternative, although it is necessary to apply doses exceeding 50 Gy which may not be always possible.
- Published
- 2010
30. [Central diabetes insipidus in adult patients--the first sign of Langerhans cell histiocytosis and Erdheim-Chester disease. Three case studies and literature review]
- Author
-
Z, Adam, K, Balsíková, M, Krejcí, L, Pour, S, Stĕpánková, P, Svacina, M, Hermanová, J, Vanícek, P, Krupa, J, Stanícek, R, Koukalová, J, Neubauer, A, Krivanová, J, Mayer, and R, Hájek
- Subjects
Adult ,Diabetes Insipidus, Neurogenic ,Diagnosis, Differential ,Male ,Erdheim-Chester Disease ,Histiocytosis, Langerhans-Cell ,Pituitary Gland ,Positron-Emission Tomography ,Humans ,Middle Aged ,Tomography, X-Ray Computed ,Magnetic Resonance Imaging - Abstract
Central diabetes insipidus with an onset in adulthood is very rare. Unlike in children, central diabetes insipidus in adults is more frequently caused by inflammatory processes and neoplastic infiltrations that do not originate from the neuronal tissue than primary neuronal tissue tumours. Rare histiocytic neoplasias (Langerhans cell histiocytosis, xanthogranulomatosis and Erdheim-Chester disease) have a specific affinity to hypothalamus and the pituitary stalk not only in paediatric patients but also when occurring in adults. We describe 3 cases of central diabetes insipidus with an onset in adulthood. Diabetes insipidus was the first sign of Langerhans cell histiocytosis in 2 patients, and it was the first sign of Erdheim-Chester disease in one patient. MR imaging showed pathological infiltration and dilated pituitary stalks in all 3 patients. PET-CT proved useful in differential diagnosis, showing further extracranial pathological changes either on the basis of significant glucose accumulation or on the basis of CT imaging. The Langerhans cell histiocytosis in the first patient has also manifested itself as an infiltration of the perianal area with intensive accumulation of fluorodeoxyglucose (FDG) - SUV 8.6 and gingival inflammation indistinguishable from parodontosis. Histology of the perianal infiltrate confirmed Langerhans cell histiocytosis. Infiltration of the pituitary stalk disappeared from the MR image after 4 cycles of 2-chlordeoxyadenosin (5 mg/m2 5 consecutive days). The PET-CT of the 2nd patient showed only borderline accumulation of FDG in the ENT area, while simultaneously performed CT imaging showed cystic restructuring of the pulmonary parenchyma and nodulations consistent with pulmonary Langerhans cell histiocytosis. Bronchoalveolar lavage identified higher number of CD1 and S100 positive elements, consistent, once again, with pulmonary LCH also affecting pituitary stalk and ear canal. The PET-CT of the third patient showed increased activity in the long bones and ilium near the sacroiliac joint. Biopsy of the focus in the ilium confirmed foam histiocyte infiltration immunochemically corresponding to Erdheim-Chester disease. Additional imaging assessments revealed the presence of further signs of the disease. Pituitary infiltrate biopsy in this patient did not elucidate the diagnosis but resulted in complete panhypopituarism. Central diabetes insipidus in adulthood might be the first sign of so far undiagnosed extracranial disease, in our case of histiocytic neoplasias, and PET-CT has an excellent potential to detect extracranial symptoms of these conditions. Therefore, the high-risk pituitary stalk infiltrate biopsy should always be preceded by comprehensive examination aimed at identification of extracranial manifestations of the pituitary gland diseases.
- Published
- 2010
31. [Monoclonal gammopathies of undetermined significance]
- Author
-
V, Krizalkovicová, V, Maisnar, L, Pour, J, Radocha, and R, Hájek
- Subjects
Paraproteinemias ,Humans ,Monoclonal Gammopathy of Undetermined Significance - Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is the most common type of monoclonal gammopathies. Genetic changes, various cytokines and bone marrow angiogenesis play an important role in the pathogenesis. As far as the malignant transformation of MGUS is concerned, size and type of the serum M-protein, serum kappa and lambda free light chain ratio and number of plasma cells in peripheral blood seem to play a predictive role. A new possible risk-stratification model predicting progression of MGUS to multiple myeloma or other related disorders was presented in 2006. The model takes three parametres in consideration, type and initial size of the serum M-protein and serum kappa and lambda ratio. Patients are divided into four risk groups with different risk of progression, from 5% at 20 years in low risk group to 58% in high risk group. The interval from MGUS diagnosis to the evolution of multiple myeloma or other related malignancies ranges from 1 to 30 years. Nevertheless, the risk of progression persists even after more than 30 years after MGUS diagnosis.
- Published
- 2008
32. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
- Author
-
M, Zemanova, V, Scudla, Z, Adam, E, Gregora, L, Pour, J, Minarik, P, Pavlicek, T, Pika, and J, Bacovsky
- Subjects
Male ,Salvage Therapy ,Middle Aged ,Dexamethasone ,Thalidomide ,Treatment Outcome ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,Drug Evaluation ,Humans ,Female ,Multiple Myeloma ,Cyclophosphamide ,Aged - Abstract
Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma. Recently, several studies have shown very good results in therapy combination of thalidomide, cyclophosphamide and dexamethasone, but still high doses of thalidomide associated with serious adverse events have been used. In our study, we performed low-dose thalidomide regimens; the aim of this study was to verify the effect and to assess their toxicity. For younger patients up to 65 years we used a "CTD-junior" regimen, consisting of oral thalidomide 200 mg daily, pulsed intravenous cyclophosphamide 800 mg on day 1 and pulsed oral dexamethasone 40 mg on days 1-4 and 12-15, for every three weeks. For patients over 65 years, the "CTDsenior" regimen was used, with oral thalidomide 50-100 mg daily (according to tolerability), oral cyclophosphamide 50 mg daily and pulsed dexamethasone 20 mg on days 1-4 and 15-18, for every four weeks. From the group of 97 patients with progressive form of multiple myeloma or with resistance to conventional chemotherapy, 85 patients were evaluated. According to the EBMT criteria, we observed in 8% complete remission (CR), in 50% partial response (PR) and in 22% minimal response (MR). Ten patients (12%) were stabilized and seven patients (8%) progressed. Toxicity of both regimens was mild and well manageable, when weakness, obstipation, neuropathy of lower extremities, glycoregulation worsening and mild leucopenia occurred most often. These results showed that low doses of thalidomide are still effective, when combined with other drugs. Both CTD regimens are safe also for patients with advanced and heavily pretreated multiple myeloma.
- Published
- 2008
33. [How to determine whether a compressive spinal fracture was caused by osteoporosis or multiple myeloma]
- Author
-
J, Neubauer, Z, Adam, and L, Pour
- Subjects
Diagnosis, Differential ,Biopsy ,Fractures, Compression ,Paraproteinemias ,Humans ,Spinal Fractures ,Female ,Diagnostic Errors ,Multiple Myeloma ,Osteoporosis, Postmenopausal ,Aged - Abstract
The most common cause of compressive spinal fractures in older women is undoubtedly senile osteoporosis, while less common causes are malignant diseases which metastase into the skeleton and multiple myeloma focally or diffusely infiltrating the skeleton. Targeted biopsy in the hands of an experienced radiologist is the fastest diagnostic method which has the potential to detect the exact cause of the compressive fracture. We describe a case of monoclonal gammopathy in which only a biopsy using CT-guided puncture of the compressed vertebra showed a symptomatic multiple myeloma requiring overall treatment. Up to the time of the targeted biopsy, the patient had wrongly been classified as a case of monoclonal gammopathy of undetermined significance, and later as a case of stage IA asymptomatic multiple myeloma. The aim of the paper is to draw attention to the need for early invasive diagnostic intervention in unclear cases.
- Published
- 2008
34. [Recommendations for early identification of damage to the skeleton by malignant processes, and for early diagnosis of multiple myeloma]
- Author
-
Z, Adam, J, Bednarík, J, Neubauer, R, Chaloupka, Z, Fojtík, J, Vanícek, L, Pour, Z, Cermákova, V, Scudla, V, Maisnar, J, Straub, M, Schützová, E, Gregora, M, Weinreb, K, Stuchlíková, J, Stanícek, R, Hájek, M, Krejcí, and J, Vorlícek
- Subjects
Radiography ,Early Diagnosis ,Humans ,Multiple Myeloma ,Bone and Bones - Abstract
The number of newly diagnosed cases of multiple myeloma in the Czech Republic is about 3-4 per 100 000 persons per year. In the higher age groups, the incidence increases. Multiple myeloma is an illness that reacts well to treatment which can result in periods of remission lasting for years. Some of the patients are even able to return to work. A pre-requisite for successful treatment is early diagnosis and this is usually in the hands of first line physicians. This is the reason why the Czech Myeloma Group, in conjunction with neurologists, orthopedicians and radio diagnosticians has issued the following recommendations for first line physicians containing a more detailed description of the symptoms and the diagnostic pitfalls of the disease. This disease reminds a chameleon for the variety of its symptoms. For the sake of clarification, we shall divide multiple myeloma symptoms into five points, each of which is reason enough to warrant an examination to confirm or rule out a malignant cause of health problems (a negative result does not automatically mean exclusion). If any of the recommended examinations results positive, the diagnostic process must be continued, in which case a general practitioner refers the patient to a specialist health centre. Observing these recommendations should minimize the number of cases of late diagnosis. 1. Bone destruction symptoms. - Unexplained backache for more than one month in any part of spine even without nerve root irritability or without pain in other part of skeleton (ribs, hips, or long bones). - Pain at the beginning of myeloma disease is very similar to benigne common discopathy, however the intensity of backache is decreasing within one months in benigne disease. In the case of malignant process the intensity of bone pain is steadily increasing. - Immediate imaging and laboratory investigation are indicated by resting and night pain in spinal column or in any part of skeleton. - Backache with the sign of spinal cord or nerve compression should be sent for immediate X Ray, and focussed CT/MRI followed by acute surgery if needed. - Osteoporosis especially in men and premenopausal women. 2. Features of changed immunity or bone marrow function. Persistent and recurrent infection, typical is normochromic anaemia, with leucopenia and trombocytopenia. 3. Raised erythrocyte sedimentation rate even increase concentration of total plasma protein. 4. Impaired renal function. Increased level of creatinin or proteinuria, nephrotic syndrome with bilateral legs oedema. 5. Hypercalcemia with typical clinical symptoms (polyuria with dehydratation, constipation, nausea, low level conscience, coma). Every one from these points has to be reason for general medical doctor to start battery of tests: -X-ray of bones focused to painful area (mandatory before physiotherapy, local anaesthesia or other empiric therapy). If plain X-ray does not elucidate pain and symptoms are lasting more than one month, please consider all circumstances and results from laboratory investigation. This patient needs referral to the centre with MRI/CT facilities (CT or MRI is necessary investigation in case of nerve root or spine compression). -Investigation of erythrocyte sedimantion rate (high level of sedimentation of erythrocyte can indicate multiple myeloma). -Full blood count. -Basic biochemical investigation serum and urine: serum urea, creatinin, ionts including calcium, total protein, and albumin CRP (high concentration of total protein indicates myeloma, low level of albumin indicates general pathological process, similary increased concentration of fibrinogen, impaired renal function indicates myeloma kidney, however hypercalcemia is typical for highly aggressive myeloma). -Quantitative screening for IgG, IgM and IgA in serum (isolated raised level one of immunoglobulin with decreased level of the others indicates myeloma). -Common electrophoresis of serum is able to detect monoclonal immunoglobulin level at few gramm concentration. If all the laboratory investigation are in normal level the possibility that the current problems are multiple myeloma origine is smaller, but it does not exclude one of rare variant--non secretory myeloma (undifferentiated plasmocyt lost characteristic feature to produce monoclonal immunoglobulin). If any of tests indicate the possibility of myeloma, patient require urgent specialist referral to department with possibility to make diagnosis of malignant myeloma.
- Published
- 2008
35. [Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration]
- Author
-
Z, Adam, M, Kozumpliková, L, Pour, and M, Machálka
- Subjects
Adult ,Male ,Diphosphonates ,Osteonecrosis ,Humans ,Multiple Myeloma ,Jaw Diseases - Abstract
The osteonecrosis of jaws is a phenomena newly described in the connection with bisphosphonate therapy. We describe a case of a 41 years old man with multiple myeloma, who developed the osteonecrosis of jaw in the course of antimyeloma therapy. The men had tooth pain from the beginning of the chemotherapy, but the extraction was performed till one month before high dose chemotherapy with peripheral stem cell transplantations, when the conservative therapy was find unsatisfactory. Bisphosphonate were administered from the beginning of the chemotherapy, the bisphosphonate therapy was started with clodronate and later changed to zoledronate. One year from the tooth extraction the wound did not heeled and therefore resection of the necrotic bone was performed. The pain in the jaw was diminished, but the wound is not completely heeled. The administration of bisphosphonate was stopped after the diagnosis osteonecrosis of the jaws.
- Published
- 2006
36. Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease.
- Author
-
M., Zatopkova, J., Filipova, T., Jelinek, P., Vojta, T., Sevcikova, M., Simicek, L., Rihova, R., Bezdekova, K., Growkova, Z., Kufova, J., Smejkalova, M., Hajduch, L., Pour, J., Minarik, A., Jungova, V., Maisnar, F., Kryukov, and R., Hajek
- Published
- 2017
- Full Text
- View/download PDF
37. Biomarkers in Immunoglobulin Light Chain Amyloidosis.
- Author
-
Z., Kufova, T., Sevcikova, K., Growkova, P., Vojta, J., Filipova, Z., Adam, L., Pour, M., Penka, R., Rysava, P., Nemec, L., Brozova, P., Vychytilova, A., Jurczyszyn, S., Grosicki, A., Barchnicka, M., Hajduch, M., Simicek, and R., Hajek
- Published
- 2017
- Full Text
- View/download PDF
38. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.
- Author
-
L., Brozova, D., Schwarz, I., Snabl, J., Kalina, B., Pavlickova, M., Komenda, J., Jarkovsky, P., Nemec, D., Horinek, Z., Stefanikova, L., Pour, R., Hajek, and V., Maisnar
- Published
- 2017
- Full Text
- View/download PDF
39. Asymp tomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
- Author
-
L., Brozova, J., Jarkovsky, L., Pour, J., Minarik, A., Jungova, E., Gregora, I., Spicka, V., Maisnar, and R., Hajek
- Published
- 2017
- Full Text
- View/download PDF
40. Liquid Biopsies - the Clinics and the Molecules.
- Author
-
V., Kubaczkova, L., Sedlarikova, B., Bollova, V., Sandecka, M., Stork, L., Pour, and S., Sevcikova
- Published
- 2017
- Full Text
- View/download PDF
41. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
- Author
-
L., Rihova, P., Vsianska, R., Bezdekova, R., Kralova, M., Penka, M., Krejci, L., Pour, and R., Hajek
- Published
- 2017
- Full Text
- View/download PDF
42. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma]
- Author
-
J, Smejkalová, V, Vranová, A, Oltová, P, Kuglík, H, Filková, J, Heinigová, L, Kovárová, Z, Adam, M, Krejcí, L, Pour, T, Büchler, A, Svobodník, S, Vostrejsová, V, Kalábová, J, Vorlícek, M, Penka, and R, Hájek
- Subjects
Male ,Chromosomes, Human, Pair 13 ,Immunomagnetic Separation ,Humans ,Bone Marrow Cells ,Female ,Chromosome Deletion ,Multiple Myeloma ,Prognosis ,Interphase ,Cells, Cultured ,In Situ Hybridization, Fluorescence - Abstract
Cytogenetic abnormalities of chromosome 13 are emerging as important prognostic factors in multiple myeloma and have been associated with poor prognosis.The occurrence of 13q14 deletion and other standard laboratory parameters were determined in 40 patients with multiple myeloma. We found that interphase fluorescence in situ hybridization using a locus specific probe for RB1 gene on immunomagnetically selected myeloma cells was more sensitive than non selected cells. The 13q14 deletion was found in 10 of 40 (25.0%) of bone marrow samples without cell selection and in 25 of 40 (62.5%) of samples with CD138+ enriched myeloma cells. Negative correlation was found between albumin and the 13q14 deletion in separated (p = 0.003) as well as in cells without selection (p = 0.010). No significant correlation was found in overall survival of separated and unseparated cells (p = 0.830; p = 0.260) and a similar result was obtained for treatment response after transplantation of separated cells (p = 0.520) or non-separated cells (0.190).Our results confirm that immunomagnetic selection of CD138+ cells increases the probability of detection of the 13q14 deletion in bone marrow samples. The correlation was found between albumin and the 13q14 deletion in both of type of cells.
- Published
- 2005
43. [Angiogenesis and antiangiogenic cancer therapy]
- Author
-
L, Pour, R, Hájek, T, Buchler, V, Maisnar, and L, Smolej
- Subjects
Neovascularization, Pathologic ,Neoplasms ,Humans ,Angiogenesis Inhibitors - Abstract
Physiologic angiogenesis takes place during tissue growth and repair, during the female reproductive cycle, and during fetal development. Angiogenesis is also required for tumor growth and metastasis and, therefore, represents an exciting target for cancer treatment. Angiogenesis is a complex process that is tightly regulated by pro- and antiangiogenic growth factors. Pathologic angiogenesis is characterized by either excessive (eg. cancer) or inadequate (eg. coronary artery disease) neovascularization. Avascular tumors are severely restricted in their growth potential because of the lack of a blood supply. For tumors to develop in size and metastatic potential they must make an "angiogenic switch" through perturbing the local balance of proangiogenic and antiangiogenic factors. Frequently, tumors overexpress proangiogenic factors, such as vascular endothelial growth factor, allowing them to make this angiogenic switch. Two strategies used in the development of antiangiogenic agents involve the inhibition of proangiogenic factors (eg. anti-vascular endothelial growth factor monoclonal antibodies) as well as therapy with endogenous inhibitors of angiogenesis. Emerging antiangiogenic agents currently in clinical studies are discussed in this review.
- Published
- 2005
44. Impact of Number of Previous Treatment Lines and Pre-Treatment with Bortezomib or Lenalidomide on Efficacy of Bortezomib-Bendamustine-Dexamethasone (BBD) in Patients with Relapsed/Refractory Multiple Myeloma (MM)
- Author
-
Richard Greil, Z. Adam, Heinz Ludwig, N. Zojer, M. Fillitz, Werner Linkesch, C. Leitgeb, E. Rauch, L. Pour, and H. Kasparu
- Subjects
Bendamustine ,medicine.medical_specialty ,Bortezomib ,business.industry ,Hematology ,medicine.disease ,Gastroenterology ,Discontinuation ,Oncology ,Median follow-up ,Internal medicine ,medicine ,business ,Dexamethasone ,Survival analysis ,Multiple myeloma ,medicine.drug ,Lenalidomide - Abstract
Introduction The number of previous treatment lines and pre-treatment with Bortezomib (B) or lenalidomide (L) likely impacts the efficacy and tolerance of BBD in r/rMM. Patients and methods 71 pts with r/rMM have been enrolled. Median age: 65 yrs (range 40-86), male/female: 32/39, ISS stage I/II/III: 22, 29, and 20 pts, respectively. ECOG status 0/I/II: 37, 31, and 3 pts, respectively. Previous treatment lines: 1-2: 44, 3-6: 27 pts, 43 pts had previously been exposed to B and 37 to L. Full data documentation for response evaluation (≥2 cycles) is available for 65 pts. Treatment Benda 70 mg/m2 day 1 + 4, B 1.3 mg/m2 and Dex 20 mg on days 1, 4, 8 and 11, q 4 wks. Planned number of treatment cycles was 8, with discontinuation after 4 cycles in case of no response. K-M survival curves were compared using the log-rank test. Results After a median follow up of 7.1 mos, myeloma response (ORR: CR-PR) was noted in 38 (58.5%), CR/nCR in 11 (16.9%), VGPR in 10 (15.4%), PR in 17 (26.2%), MR in 11 (16.9%), and SD in 16 (24.6%) pts. Median time to response was 77 days. Tab 1 shows response rates and PFS in pts in regards to number of previous treatment lines and pre-exposure to B, L, and to both B and L. Median OS was not reached in any of the cohorts. All Pts 1-2 Treatment lines 3-6 Treatment lines Pre-exposure B L B and L ORR (%) 58.5% 61% 54% 76% 60% 44% PFS (mos) 12.2 13.0 7.8 12.2 5.9 6.0 G4 anemia, leucopenia and thrombopenia were reported in Disclosure H. Ludwig: Received honoraria for speakers bureau from Mundipharma, Celgene and Janssen-Cilag. Scientific research grants from Mundipharma and Janssen-Cilag. All other authors have declared no conflicts of interest.
- Published
- 2012
45. Hydrological Behaviour of Tritium on the Former Semipalatinsk Nuclear Test Site (Kazakhstan) Determined using Stable Isotope Measurements
- Author
-
L. Pourcelot, L. Leon Vintro, P. I. Mitchell, M. Burkitbayev, B. Uralbekov, A. Bolatov, Y. Strilchuk, J-M Metivier, and N. D. Priest
- Subjects
Chemistry ,QD1-999 - Abstract
Tritium and stable isotope (deuterium 2H and 18O) concentrations have been determined in natural waters collected from shallow lakes, wells, streams and rivers inside and in the vicinity of the former Semipalatinsk Nuclear Test Site (NE Kazakhstan). The Semipalatinsk Test Site (STS) was one of the main proving grounds for the testing of nuclear weapons by the former Soviet Union. Tritium activity concentrations have been determined by liquid scintillation counting, while hydrogen isotopic composition have been determined using a GV-Isoprime mass spectrometer coupled to an elemental analyzer. Tritium activity concentrations recorded in lake waters (in most cases >10 Bq L-1) were significantly higher than those in well, stream and the Irtysh River waters. In lake waters, enrichments in deuterium and 18O (δD and δ18O varying between –5 and –64 ‰ V-SMOW and –8.4 and +5.5 ‰ V-SMOW, respectively), and high salt concentrations, strongly suggest that significant evaporation has occurred. In contrast, deuterium and tritium signatures of ‘common’ surface and underground waters at the STS were mostly typical of present-day isotope backgrounds of natural waters in NE Kazakhstan. In STS, come salt lakes like Bajansor and Tumatsor with elevated tritium activity from 12 to 15 Bq L-1 lie close to the Global Meteoric Water Line. The potential tritium source for these lakes is residual concentration of tritium after former nuclear test in STS. The study provides evidence to show that export of tritium from underground nuclear test areas and tritium enrichment produced by evaporation are both important determinants of tritium concentrations in standing waters on the Semipalatinsk test site.
- Published
- 2013
- Full Text
- View/download PDF
46. Study of climatic conditions for tourism development using TCI indicator (Case study East Azerbaijan province)
- Author
-
H. Yazdanpanah, M. Abdoallahzadeh, and L. Poureidivand
- Subjects
Tourism ,Climate ,East Azerbaijan ,TCI index. ,Geography (General) ,G1-922 ,Environmental sciences ,GE1-350 - Abstract
Extended Abstract1- IntroductionTourism makes up a large part of the global economy and often as a key to economic growth in both developing and developed countries is used. One of the factors that should be considered in tourism is climate. Because in many countries of weather and climate are considered a capital value for tourism. But until now the source of tourism, tourism has a major role in the educational literature. Since much of modern tourism based on the use of natural features - is based on physical, development of tourist sites was not dependent on one source; it involves a wide range of resources, especially natural resources. The climate is considered as a source of basic or supplemental. So that from that day climate comfort that tourists visit places to go It is very important for planners and planners to climatic data before, after and during the visit to places of need. The study characteristics and climatic differences and variations in time and space that govern their relationship with human activities, Ways in order to analyze the environmental conditions within the planning of tourism offers. Tourism is important to determine the index for more comfort. Comfort tourism climate index (TCI) is a combination of methods that were presented in 1985 by Mieczkowski. The TCI is a combination of factors affecting the comfort of tourists. The index, climatic comfort of the tourists the best travel time is determined. Also, the calculation for different regions or even the wider world in the remarkable contribution to the tourist destination of choice. East Azerbaijan province with many features and attractions for the tourism industry and attract tourism, But such is not worthy of the blessings that will benefit the industry, Using the climatic comfort of tourists can be accurately planned and managed to attract tourists to this lucrative industry.2- MethodologyIn this study, the studies of climatic conditions in East Azerbaijan province, to develop tourism in this province have dealt with the use of TCI. Due to the nature component of the approach to study the situation "a descriptive-analytic”. The purpose of this research, applied research and in literature, documents and library data collection method is used. In addition to analyzing data from Excel and GIS software is used. In this case, the first climate data from meteorological synoptic station is not needed in East Azerbaijan province, for a period of 20 years (2010-1990) were collected And then using TCI in different stages of 1)-calculation of daily comfort index (CID), variables that are used in this index, The maximum daily temperature and average minimum daily relative humidity is. 2) Boarding comfort index (CIA), variables that are used in this index includes the average daily temperature and average daily relative humidity. 3) Roth calculating rainfall (R), 4) - calculation Rtbh number of sunshine hours (S), 5)-Rtbh calculation of air flow (the mean wind speed) (W)), the province's tourism climate comfort for each of the stations in different seasons were calculated. The TCI index stations for each month of the year, the results were entered into GIS software environment. According to the results obtained point to be, Comfort conditions for climate zones across the province-level data point to be generalized. In order to generalize the results point to the entire surface of the image distance weighting interpolation method (IDW) have used and to the point of information stations will be converted to surface and TCI and maps for the entire province is obtained.3- DiscussionIn East Azerbaijan province, as one of the main tourist poles of various natural attractions, historical, cultural and prevailing climatic conditions in different regions of the province, in different seasons, the weather can be a factor be made to attract tourists. So that the quantitative evaluation Ptansl and detailed information about them can be made better use of these capabilities. Tourism in the comfort of the climate in different regions of East Azerbaijan province, the calculation of climatic parameters in each of the TCI and Rtbh each of the stations of various climate parameters, The ratings obtained for each of the parameters for each of the stations Metals replaced in the index formula and for each station in different seasons of the numerical value obtained among the rank and 0-100 are located. Indicate that climatic conditions so intolerable situation is ideal. The results of the index, the number of zones in the province climatourism GIS environment was used And the proportion and number of classes in different seasons for each station have the comfort of the climate is classified as tourists.4- ConclusionIn recent years the influence of climatic factors on tourists' satisfaction, increased sensitivity and its importance in selecting a suitable place for tourists are staying. In this study, climate comfort for the tourists in the month of separation of East Azerbaijan province (TCI) used to have. The results were used to determine the climatic comfort of TCI in East Azerbaijan province, indicating that this index is a large variation in different regions of the province. So that the annual index of TCI in the months of May, June, July, August and September (May, June, July, August and September) with the best conditions of climatic comfort of the tourists are and January, February, November and March (December, January, February and March) due to the dominance of the high-pressure system, with the worst of these conditions are considered. Examine and compare the results of the TCI index for different regions of the province, and showed consistent results fit with the realities of the region's climate.Key Words: Tourism, Climate, East Azerbaijan, TCI index.ReferencesAmelung.B and Viner.D (2006): Mediterranean Tourism: Exploring The Futur With The Tourism Climatic Index, Journal Of Sustainable Tourism. 0966-9582/040349-18.Management and Planning Organization of East Azerbaijan province, (1376) TV province, emissions management.Ramezani, Bahman (2006): Identifying potential wetland eco ecotourism comfort Kyaklayh Langrood Evans method, Journal of Geography and Regional Development.Sarraf, B. and T. Azin Jalali and Jalal Kamali (2010): Regional zoning Klymatvrysm Arasbaran use of TCI, of geographical space, in the tenth, Number 30, Summer 1389worth, and V. S. Heshmat Feizi and Agriculture (2009): Study climate Kish islands for tourism development with the use of TCI, the fifth national conference of selected papers of the Arabian Gulf.Zyay, Mahmoud and Rshyn Bakhtiari (2009): Climate comfort tourist islands of Kish, the fifth conference of selected papers of the Arabian Gulf.Bynoe, Dennylewis, Howard, Stacia and Mppre, Winston (2002):Climate Change And Tourism Features In The Caribban, Munich Personal Repec Archive (MPRA), C43:Q5:L83. Daniel Scott, Geoff McBoyle, Michael Schwartzentruber (2004): Climate change and the distribution of climatic resources for tourism in North America, department of geography, university of waterloo,200 university avenue west, waterloo,Ontario N2L 3G1, Canada.vol.27:105-117.De Freitas,CR, Daniel Scott, Geff McBoyle (2008): A,secondgeneration climate index for tourism(CIT)specification and verification.Font Xavier and Ahjem Tor E (1999), Searching for a balance in tourism development strategies, international journal of contemporary.Eccles Gavin, Costa Jorge (1996),Perspectives on tourism development, International Journal of Contemporary Hospitality Management, Volume:8 Number:7 pp: 44-51Gomez Martin, M (2000):Climate and Tourism in Catalonia: assessment of the climate- tourist potential of the aestival station.OHD dissertation in geography, University of Barselona.Matzarakis, Andreas (2001): Climate andbioclimate information for tourism in Greece, Meteorological Institute, University of Freiborg, Werderring 10, D-79085 Freiborg, Germany.Mieczkowski. Z (1985): The tourism climatic index: a method of avaluating world climats for tourism. The Canadian Geografer,29: 220-233.Maureen D.Agnew and Jean P.Palutikof (2001): Climate Impacts On The Demand For TOURISM, climat research unit, school of environmental sciences, university of east anglia, Norwich, united kingdom, NR4 7TJ.Monferrand, A (2002): The weather, a major hazard in the tourist frequenting, Espaces, tourism and loisirs 190:22- 24.Rense, W.C(1974): Weather as an influencing factor in the use of Oregons coastal recreation areas.Ph.D. thesis, Dept of Geography, Oregon State University,pp 217.Scott, Daniel, McBoyle, Geoff and Schwartzentruber, Michael (2004): Climate change and the distribution of climatic resources for tourism in North America, department of geography, university of waterloo,200 university avenue west, waterloo,Ontario N2L 3G1, Canada.vol.27:105-117.www.mpo.as.ir Alijani, Bohlooli, Mohammad Reza Kaviani (2006): Principles of Climate Science, the publisher.Ebrahim zadeh, Isa and Abdullah, Aghassi was born (2009): Analysis of factors affecting the development of tourism in the coastal region of Cahaba with the use of strategic models SOWT, Urban and Regional Studies and Research, the first year, the first issue, Summer.Ebrahimi, Abdul Hamid and colleagues (2010): The effect of advertising to attract tourists (case study: international tourists in city Isfahan), Geography and Development, No. 17, Spring.Esmaili, R. and Akram Saber Truth (2010): Evaluation of climate comfort in the Chabahar port for tourism development, "Proceedings of the Fourth International Congress of Geographers of the Islamic World", Journal, April 2010.Farzin, MR (2008): economy, tourism, commercial printing and publishing companies affiliated with the Institute of Business Studies and Research.Kasmaee, M. (1993): Iran's climatic zoning, housing and residential environments, Building and Housing Research Center, No. 151, Tehran.Kazemi, M. (2007): Tourism Management, second edition, Tehran: SAMT.Tavallaie, Simin (2007): Review of the tourism industry, Teacher Training University. Tehran.Zahedi, Shams al-Sadat (2006): Principles of Ecotourism (with emphasis on the environment), Printing, Tehran: Allameh Tabatabai University.Zulfaqary, H. (2007): Determination of the appropriate calendar time working in Tabriz, using indices of physiological temperature and the predicted average rating, Geographical Research, No. 62, Winter.
- Published
- 2013
47. The Solid Speciation of 90Sr, 137Cs, 226Ra, 238U and 239,240Pu in Surface Soils from Sites of Special Radiological Interest in Kazakhstan
- Author
-
M. Burkitbayev, M. Conway, H. Jimenez Napoles, Y. Kuyanova, L. León Vintró, P.I. Mitchell, N.D. Priest, L. Pourselot, P. Stegnar, B. Salbu, and B. Uralbekov
- Subjects
Chemistry ,QD1-999 - Abstract
The solid speciation of some radiologically important radioelements has been examined in soils sampled at the former Semipalatinsk (Nuclear) Test Site (STS) and at Kurdai, the site of a former major uranium mining operation − both situated in Kazakhstan. Specifically, the partitioning of radiostrontium, radiocaesium and plutonium has been examined using sequential extraction on selected soils from the test site, while the partitioning of radium and uranium has been evaluated in soils at Kurdai. The data show that at the STS, in general, little (if any) of the radiostrontium, radiocaesium and plutonium is in an exchangeable form, with the great bulk of the radiostrontium and radiocaesium in a strongly bound or refractory form. In the case of plutonium, the proportion in a strongly bound or refractory form varies from 40% to 95% depending on site and appears to be a function of the explosive yield involved. At the Kurdai ore deposit, less than 5% of the uranium and radium is in an exchangeable form, with some 35-60% of the uranium and the bulk of the radium in a strongly bound or residual form.
- Published
- 2009
- Full Text
- View/download PDF
48. Diameters and geodesic properties of generalizations of the associahedron
- Author
-
C. Ceballos, T. Manneville, V. Pilaud, and L. Pournin
- Subjects
flip graph diameter ,non-leaving-face property ,generalized associahedra ,graph associahedra ,[info.info-dm] computer science [cs]/discrete mathematics [cs.dm] ,Mathematics ,QA1-939 - Abstract
The $n$-dimensional associahedron is a polytope whose vertices correspond to triangulations of a convex $(n + 3)$-gon and whose edges are flips between them. It was recently shown that the diameter of this polytope is $2n - 4$ as soon as $n > 9$. We study the diameters of the graphs of relevant generalizations of the associahedron: on the one hand the generalized associahedra arising from cluster algebras, and on the other hand the graph associahedra and nestohedra. Related to the diameter, we investigate the non-leaving-face property for these polytopes, which asserts that every geodesic connecting two vertices in the graph of the polytope stays in the minimal face containing both.
- Published
- 2015
- Full Text
- View/download PDF
49. ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
- Author
-
A Maiolino, R Hajek, T Jelinek, P Moreau, T Martin, L Pour, G Mikala, A Symeonidis, S Bringhen, A Rawlings, ML Risse, H Vande-Velde, and I Spicka
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objectives: Isatuximab (Isa) is an approved IgG1 monoclonal antibody that targets a specific epitope of CD38 and kills multiple myeloma (MM) cells via multiple mechanisms. The Phase 3 IKEMA study (NCT03275285) demonstrated that Isa plus carfilzomib (K) and dexamethasone (d) significantly improved progression-free survival (PFS) compared with Kd in patients (pts) with relapsed MM (hazard ratio [HR], 0.531; 99% CI, 0.32–0.89; p = 0.0007), leading to the approval of Isa-Kd in the US for adults with MM with 1–3 prior lines and in the EU for those with ≥1 prior therapy. The presence of soft-tissue plasmacytomas is associated with poor prognosis, and newer therapies are urgently needed. In this post hoc analysis, we evaluated the efficacy and safety of Isa-Kd vs Kd in pts with relapsed MM and pre-existing soft-tissue plasmacytomas. Material and methods: Pts (n = 302) were randomized (3:2) to Isa-Kd (n = 179) or Kd (n = 123). Isa (10 mg/kg IV) was given weekly for 4 weeks, then every 2 weeks. K (20 mg/m2 days 1–2, then 56 mg/m2) was given twice-weekly 3 of 4 weeks, and d (20 mg) twice-weekly. The independent review committee assessed response based on central radiology review and central lab M-protein using the International Myeloma Working Group criteria. Results: At study entry, 19 (6.3%) pts had soft-tissue plasmacytomas: 12/179 (6.7%) had Isa-Kd and 7/123 (5.7%) had Kd. Overall median (range) duration of exposure in these pts was 41.9 (2–87) weeks for Isa-Kd vs 29.9 (4–83) for Kd, with 41.7% pts still on treatment at cycle 20 in Isa-Kd vs 14.3% pts in Kd. Baseline characteristics in the plasmacytomas subgroup were similar to those in the overall IKEMA intent-to-treat (ITT) population with the exception of ISS stages II (42.1% vs 31.1%) and III (31.6% vs 15.2%), and renal function impairment (38.9% vs 22.1%) which were more prevalent in the plasmacytomas subgroup vs ITT. PFS was improved with Isa-Kd vs Kd: HR, 0.574; 95% CI, 0.125–2.640. Median PFS was 18.76 (95% CI, 4.435–not calculable [NC]) months with Isa-Kd vs NC (0.986–NC) months with Kd. Overall response rate (50.0% vs 28.6%), very good partial response or better (33.3% vs 14.3%), and complete response (25.0% vs 0%, all with minimal residual disease negativity) rates were also improved with Isa-Kd vs Kd. Grade ≥3 TEAE occurred in 12 (100%) pts with Isa-Kd vs 4 (57.1%) with Kd. Grade 5 TEAEs during study treatment occurred in 2 (16.7%) vs 1 (14.3%) pt; serious TEAEs in 9 (75.0%) vs 4 (57.1%); TEAEs leading to discontinuations were 0 (0%) vs 1 (14.3%). Grade 5 events were pneumonia (1 [8.3%], Isa-Kd) and progressive disease (1 [8.3%], Isa-Kd; 1 [14.3%], Kd). Conclusions: In pts with relapsed MM and soft-tissue plasmacytomas, Isa-Kd improved PFS and depth of response compared with Kd alone, with a manageable safety profile, consistent with the benefit observed in the IKEMA study overall population. Isa-Kd is a new treatment option for pts with relapsed MM and soft-tissue plasmacytomas. Funding: Sanofi.
- Published
- 2021
- Full Text
- View/download PDF
50. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results
- Author
-
Viera Sandecká, Marta Krejčí, Darina Očadlíková, Lenka Zahradová, Klára Mollová, L. Kovarova, Krivanová A, Zdeněk Adam, Roman Hájek, Luděk Pour, L. ZAHRADOVA, K. MOLLOVA, D. OCADLIKOVA, L. KOVAROVA, Z. ADAM, M. KREJCI, L. POUR, A. KRIVANOVA, V. SANDECKA, and R. HAJEK
- Subjects
Male ,Cancer Research ,dendritic cell ,medicine.medical_treatment ,Phases of clinical research ,Enzyme-Linked Immunosorbent Assay ,Cancer Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Adjuvants, Immunologic ,medicine ,Humans ,Cumulative incidence ,Hypersensitivity, Delayed ,Survival rate ,Multiple myeloma ,030304 developmental biology ,Aged ,Neoplasm Staging ,0303 health sciences ,business.industry ,ELISPOT ,anticancer vaccine ,Vaccination ,Immunotherapy ,Dendritic Cells ,Id-protein ,Middle Aged ,medicine.disease ,Prognosis ,3. Good health ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Case-Control Studies ,Immunology ,Hemocyanins ,Female ,Inhibitor of Differentiation Proteins ,business ,Multiple Myeloma - Abstract
In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p= 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.dendritic cells, immunotherapy, anticancer vaccines, Id-protein, multiple myeloma.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.